UA97349C2 - Стійкі тверді склади сертиндолу - Google Patents

Стійкі тверді склади сертиндолу Download PDF

Info

Publication number: UA97349C2
Authority: UA; Ukraine
Prior art keywords: coating layer; sertindole; amount; iron oxide; dosage form
Prior art date: 2005-09-08

Application number

UAA200803569A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Флемминг Энок Ольсен

Анна Равнхольдт Христенсен

Кен Лильегрен

Original Assignee

Х. Луннбэк А/С

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-08

Filing date

2006-06-09

Publication date

2012-02-10

2006-06-09 Application filed by Х. Луннбэк А/С filed Critical Х. Луннбэк А/С

2012-02-10 Publication of UA97349C2 publication Critical patent/UA97349C2/uk

Links

GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 title claims abstract description 55
229960000652 sertindole Drugs 0.000 title claims abstract description 52
239000000203 mixture Substances 0.000 title claims description 37
239000007787 solid Substances 0.000 title description 19
238000009472 formulation Methods 0.000 title description 7
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims abstract description 84
239000011247 coating layer Substances 0.000 claims abstract description 37
239000006187 pill Substances 0.000 claims description 52
239000010410 layer Substances 0.000 claims description 32
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 24
239000000126 substance Substances 0.000 claims description 24
239000002775 capsule Substances 0.000 claims description 18
239000007888 film coating Substances 0.000 claims description 13
238000009501 film coating Methods 0.000 claims description 13
239000004408 titanium dioxide Substances 0.000 claims description 12
239000004014 plasticizer Substances 0.000 claims description 11
-1 acetyl triacetyl citrate Chemical compound 0.000 claims description 10
239000002202 Polyethylene glycol Substances 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 6
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 5
239000001069 triethyl citrate Substances 0.000 claims description 5
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 5
235000013769 triethyl citrate Nutrition 0.000 claims description 5
239000007909 solid dosage form Substances 0.000 claims description 4
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
239000001087 glyceryl triacetate Substances 0.000 claims description 3
235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
229960002622 triacetin Drugs 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims 8
235000013980 iron oxide Nutrition 0.000 abstract description 42
239000008194 pharmaceutical composition Substances 0.000 abstract description 23
230000005855 radiation Effects 0.000 abstract description 18
238000002360 preparation method Methods 0.000 abstract description 8
201000000980 schizophrenia Diseases 0.000 abstract description 5
JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract description 4
239000003223 protective agent Substances 0.000 abstract description 3
229960005191 ferric oxide Drugs 0.000 abstract description 2
238000000576 coating method Methods 0.000 description 22
230000001681 protective effect Effects 0.000 description 22
239000000049 pigment Substances 0.000 description 18
239000011248 coating agent Substances 0.000 description 17
150000003839 salts Chemical class 0.000 description 16
239000000725 suspension Substances 0.000 description 14
229920000642 polymer Polymers 0.000 description 13
239000000975 dye Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 10
229960003988 indigo carmine Drugs 0.000 description 10
239000004179 indigotine Substances 0.000 description 10
235000012738 indigotine Nutrition 0.000 description 10
239000000523 sample Substances 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
229910052751 metal Inorganic materials 0.000 description 8
239000002184 metal Substances 0.000 description 8
239000013068 control sample Substances 0.000 description 7
150000002739 metals Chemical class 0.000 description 7
239000000454 talc Substances 0.000 description 7
229910052623 talc Inorganic materials 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000008199 coating composition Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
229910052782 aluminium Inorganic materials 0.000 description 5
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
238000002156 mixing Methods 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
239000006229 carbon black Substances 0.000 description 4
229920002301 cellulose acetate Polymers 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
239000007857 degradation product Substances 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
235000019241 carbon black Nutrition 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000001066 destructive effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000007941 film coated tablet Substances 0.000 description 3
239000012467 final product Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 3
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000005022 packaging material Substances 0.000 description 3
229940068918 polyethylene glycol 400 Drugs 0.000 description 3
238000003860 storage Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
101150015964 Strn gene Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000561 anti-psychotic effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
230000006378 damage Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
229960001021 lactose monohydrate Drugs 0.000 description 2
239000002346 layers by function Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000010606 normalization Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
238000003825 pressing Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000009495 sugar coating Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
125000005591 trimellitate group Chemical group 0.000 description 2
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229940105289 carbon black Drugs 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
239000006255 coating slurry Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
238000004049 embossing Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000004518 granules dosage form Substances 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000009863 impact test Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000012602 primary packaging material Substances 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000012603 secondary packaging material Substances 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
229960005078 sorbitan sesquioleate Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000012463 white pigment Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Inorganic Chemistry (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UAA200803569A 2005-09-08 2006-06-09 Стійкі тверді склади сертиндолу UA97349C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200501255		2005-09-08
PCT/DK2006/050038 WO2007065448A1 (en)	2005-09-08	2006-09-06	Stable solid formulation of sertindole

Publications (1)

Publication Number	Publication Date
UA97349C2 true UA97349C2 (uk)	2012-02-10

Family

ID=37697999

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200803569A UA97349C2 (uk)	2005-09-08	2006-06-09	Стійкі тверді склади сертиндолу

Country Status (17)

Country	Link
EP (1)	EP1924261A1 (pt)
JP (1)	JP2009507051A (pt)
KR (1)	KR20080042102A (pt)
CN (1)	CN101257906A (pt)
AR (1)	AR056475A1 (pt)
AU (1)	AU2006322460A1 (pt)
BR (1)	BRPI0615630A2 (pt)
CA (1)	CA2621866A1 (pt)
EA (1)	EA013167B1 (pt)
IL (1)	IL189541A0 (pt)
MX (1)	MX2008002290A (pt)
NO (1)	NO20081721L (pt)
NZ (1)	NZ565330A (pt)
TW (1)	TW200738239A (pt)
UA (1)	UA97349C2 (pt)
WO (1)	WO2007065448A1 (pt)
ZA (1)	ZA200801169B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
WO2010087462A1 (ja) *	2009-01-29	2010-08-05	大日本住友製薬株式会社	内核を有する口腔内崩壊錠
FR2943061B1 (fr) *	2009-03-13	2011-02-25	Rhodia Operations	Composes organophosphores, systemes catalytiques comprenant ces composes et procede d'hydrocyanation ou d'hydroformylation utilisant ces systemes catalytiques
EP3470397B1 (en)	2012-07-16	2021-12-29	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
IL296484B2 (en) *	2013-06-06	2025-03-01	Fibrogen Inc	Pharmaceutical formulations of HIF hydroxylase inhibitor
US10406103B2 (en)	2013-11-19	2019-09-10	Siga Technologies Inc.	Rehydration of micronized tecovirmimat monohydrate
JP2018172361A (ja) *	2016-10-14	2018-11-08	大原薬品工業株式会社	光安定性を改善した、デュロキセチンを含有する固形製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04346929A (ja) *	1991-05-22	1992-12-02	Takada Seiyaku Kk	光に安定なメシル酸ブロモクリプチン製剤
CA2250042A1 (en) *	1996-03-25	1997-10-02	Eli Lilly And Company	Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
ZA973433B (en) *	1996-04-24	1997-12-10	Shionogi & Co	A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses

2006
- 2006-06-09 UA UAA200803569A patent/UA97349C2/uk unknown
- 2006-08-17 TW TW095130202A patent/TW200738239A/zh unknown
- 2006-08-29 AR ARP060103764A patent/AR056475A1/es not_active Application Discontinuation
- 2006-09-06 JP JP2008529472A patent/JP2009507051A/ja not_active Withdrawn
- 2006-09-06 BR BRPI0615630A patent/BRPI0615630A2/pt not_active IP Right Cessation
- 2006-09-06 MX MX2008002290A patent/MX2008002290A/es not_active Application Discontinuation
- 2006-09-06 ZA ZA200801169A patent/ZA200801169B/xx unknown
- 2006-09-06 CA CA002621866A patent/CA2621866A1/en not_active Abandoned
- 2006-09-06 KR KR1020087004910A patent/KR20080042102A/ko not_active Withdrawn
- 2006-09-06 NZ NZ565330A patent/NZ565330A/en not_active IP Right Cessation
- 2006-09-06 WO PCT/DK2006/050038 patent/WO2007065448A1/en not_active Ceased
- 2006-09-06 AU AU2006322460A patent/AU2006322460A1/en not_active Abandoned
- 2006-09-06 EP EP06846966A patent/EP1924261A1/en not_active Withdrawn
- 2006-09-06 CN CNA2006800323410A patent/CN101257906A/zh active Pending
- 2006-09-06 EA EA200800774A patent/EA013167B1/ru not_active IP Right Cessation
2008
- 2008-02-14 IL IL189541A patent/IL189541A0/en unknown
- 2008-04-08 NO NO20081721A patent/NO20081721L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101257906A (zh)	2008-09-03
TW200738239A (en)	2007-10-16
NZ565330A (en)	2011-06-30
AU2006322460A1 (en)	2007-06-14
WO2007065448A1 (en)	2007-06-14
EA013167B1 (ru)	2010-02-26
AR056475A1 (es)	2007-10-10
BRPI0615630A2 (pt)	2016-11-16
JP2009507051A (ja)	2009-02-19
IL189541A0 (en)	2008-08-07
CA2621866A1 (en)	2007-06-14
KR20080042102A (ko)	2008-05-14
EP1924261A1 (en)	2008-05-28
EA200800774A1 (ru)	2008-06-30
ZA200801169B (en)	2010-07-28
NO20081721L (no)	2008-04-08
MX2008002290A (es)	2008-03-14

Publication	Publication Date	Title
TWI715291B (zh)	2021-01-01	包含parp抑制劑的藥物組合物
CN100490790C (zh)	2009-05-27	一种奥美拉唑肠溶微丸胶囊及其制备方法
US20090281136A1 (en)	2009-11-12	Prasugrel pharmaceutical formulations
UA44766C2 (uk)	2002-03-15	Тверда пероральна лікарська форма, до складу якої входить оланзапін, та спосіб її виготовлення
JP5365777B2 (ja)	2013-12-11	光に対して安定なラモセトロンの固形医薬組成物
JP2024033014A (ja)	2024-03-12	医薬組成物
JP2024033015A (ja)	2024-03-12	医薬品
EA029539B1 (ru)	2018-04-30	Фармацевтическая композиция ситаглиптина
JP2018008965A (ja)	2018-01-18	Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
WO2019004448A1 (ja)	2019-01-03	医薬組成物
EA013167B1 (ru)	2010-02-26	Стабильная твёрдая композиция сертиндола
US20240374527A1 (en)	2024-11-14	Pharmaceutical Composition Comprising Lumateperone
US9227938B2 (en)	2016-01-05	Pharmaceutical composition containing crystalline sorafenib tosylate
CN106668018B (zh)	2019-12-06	一种右兰索拉唑钠的缓释胶囊及其制备方法
CN119564629A (zh)	2025-03-07	一种美阿沙坦钾片及其制备方法
JP2021038209A (ja)	2021-03-11	イバブラジンを含有する錠剤
JP2020066634A (ja)	2020-04-30	腸溶性高分子及び崩壊剤を含有する顆粒
HK1123721A (en)	2009-06-26	Stable solid formulation of sertindole
HK1238250A1 (en)	2018-04-27	N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof